Embryonic stem cells (ESCs) have an unlimited proliferative capacity and extensive differentiation capability. They are an alternative source for regenerative therapies with a potential role in the treatment of several human diseases. The clinical use of ESCs, however, has significant ethical and biological obstacles related to their derivation from embryos and potential for immunological rejection, respectively. These disadvantages can be circumvented by the alternative use of induced pluripotent stem cells (iPSCs), which are generated from an individual's (autologous) somatic cells by exogenous expression of defined transcription factors and have biological characteristics similar to ESCs. In recent years, patientspecific iPSCs have been generated to study disease mechanisms and develop iPSC-based therapies. The development of iPSC-based therapies for skin diseases requires successful differentiation of iPSCs into cellular components of the skin, including epidermal keratinocytes. Here, we succeeded in generating iPSCs not only from normal human fibroblasts but also from fibroblasts isolated from the skin of two patients with recessive dystrophic epidermolysis bullosa. Moreover, we differentiated both of these iPSCs into keratinocytes with high efficiency, and generated 3D skin equivalents using iPSC-derived keratinocytes, suggesting that they were fully functional. Our studies indicate that autologous iPSCs have the potential to provide a source of cells for regenerative therapies for specific skin diseases.
ngineered human stem cells, known as induced pluripotent stem cells (iPSCs), have recently been generated from mature somatic cells by transduction of the four reprogramming transcription factors that are highly expressed in ESCs: cMYC, SOX2, OCT4, and KLF4 (1) . iPSCs are likely to have a major impact on regenerative medicine because they have proliferative characteristics and differentiation capabilities similar to those of ESCs. Deriving and using iPSCs from a patient's somatic cells can potentially circumvent the ethical and immunological issues, and also the challenges, associated with gene and cell therapy that arise from using ESCs (2) . iPSCs can be genetically modified for gene therapy and provide an unlimited source of specific cells for cell therapy. More recently, patient-specific iPSCs (PS-iPSCs) have been generated from patients with several human diseases, such as muscular dystrophy, Parkinson disease, and juvenile-onset diabetes mellitus type I, among others (3) (4) (5) (6) . These PS-iPSCs are likely to be useful tools to investigate unknown disease mechanisms, for drug testing, and to develop custom-made iPSC-based therapy for each individual (5, 6) . In one recent study, a mouse model of sickle cell anemia was successfully treated with autologous iPS cell-derived hematopoietic cells, demonstrating the therapeutic potential of this approach (7) .
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited blistering disorder caused by mutations in the COL7A1 gene encoding type VII collagen, the major component of anchoring fibrils at the basement membrane zone (BMZ). The anchoring fibrils provide the functional integrity to the skin, as they serve to adhere the epidermis to the underlying dermis (8) .
Therefore, a lack or deficiency of type VII collagen causes skin fragility, chronic blistering, and erosions. Clinically, patients with RDEB suffer from recurrent blisters involving the skin, oral mucosae, gastrointestinal tract, and genitourinary tract. Eventually, blisters in the skin heal with scarring, resulting in severe deformities, such as pseudosyndactyly (fusion of the digits) (8) . Occasionally, the blisters and erosions become infected, resulting in sepsis and multiple organ failure. The development of multiple aggressive metastatic squamous cell carcinomas is considered the most common cause of death in patients with RDEB (9) .
Currently, there is no definitive treatment for RDEB (8) , although recent progress in understanding the molecular basis of RDEB has provided a foundation for the development of cell-and gene-based therapies. One potential treatment involves engineered allografted skin from normal individuals, which is one of the well-established cell therapies for severe burn victims (10) . However, the allografted skin will eventually be immunologically rejected due to donor mismatch. Autologous skin cultures have been generated from small pieces of healthy skin isolated from burn patients, and are widely used for enhancing wound healing in instances of severe burns (10) . However, this method cannot be implemented in patients with RDEB, because functional type VII collagen protein is markedly reduced or absent from all cells of affected individuals. Recent studies demonstrated that the defect of the COL7A1 gene in basal keratinocytes isolated from patients can be replaced with COL7A1 cDNA by viral vectors (11) , and recent progress has been also made in a gene correction clinical trial of junctional EB (12) . However, gene therapy remains a challenge both because of the inability to identify and target stem cells that can assist in reconstituting all of the components of the skin, and the low efficiency of introducing the gene of interest into those cells. Furthermore, skin cells have a limited proliferative capacity, which renders them ineffective as targets for ex vivo gene therapy based on homologous recombination and as longterm sources of cell therapy.
iPSCs are well-suited for gene and cell therapy because of their origin, self-renewal capability, and pluripotency, as well as their potential for gene correction. To develop iPSC-based therapy for skin diseases, the ability to generate keratinocytes from iPSCs is a crucial prerequisite. Here, we generated iPSCs from normal individuals and two patients with RDEB, and established a protocol to differentiate these iPSCs into functional keratinocytes for effective iPSC-based therapy for diseases of the epidermis.
Results
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isolated from the foreskin of three healthy individuals and the dermis of two patients with RDEB by retroviral transduction of the four reprogramming factors, c-MYC, SOX2, OCT4, and KLF4, as previously described by Takahashi et al. (1) . After culturing the transduced cells on feeder layers, we obtained several normal iPSC lines [iPSCs from one individual were carried through the subsequent experiments (designated hiPS1 and 2), the first patient-specific iPSC (PS-iPSC) lines (hiPS-RDEB1, 2, and 3), and the second PS-iPSC lines (hiPS-RDEB4, 5, and 6)] ( Fig. 1 and Fig. S1A ). There were no significant differences in the rate and length of time required to generate iPSCs from the normal individuals and the patients with RDEB. We confirmed by genomic DNA sequence analysis that all PS-iPSC lines were in fact derived from the patients' fibroblasts, because they harbored the same mutations in the COL7A1 gene (Fig. S2 A and B) . In addition, genetic identity of PS-iPSCs was confirmed by DNA fingerprinting analysis for several microsatellite markers (Fig.  S2C) . The morphology of all iPSCs lines appeared similar to that of human ESCs (small cell shape, a large nuclear-to-cytoplasmic ratio, prominent nucleoli, and tight and flat colonies). The iPSC colonies were identified by positive alkaline phosphatase staining, and the expression of several stem cell markers, including OCT4, SOX2, SSEA3, TRA-1-60, and TRA-1-81 ( Fig. 1 and Fig. S1A ).
Whereas the four reprogramming factors were endogenously expressed in these iPSC lines, quantitative PCR showed that viral transgene silencing was observed, although it varied among the lines ( Fig. 2A and Fig. S1B ). We also demonstrated by RT-PCR that additional pluripotent markers were expressed in both normal and PS-iPSCs, as well as ESCs ( Fig. 2B and Fig. S1C ). iPSCs grew at similar rates to human ESCs and maintained normal karyotypes (46, XY) ( Fig. 2C and Fig. S1D ). Bisulfite sequencing revealed that the NANOG promoter region in these iPSCs were demethylated in a pattern similar to ESCs, demonstrating that our iPSCs were epigenetically reprogrammed and that the NANOG promoter was reactivated in these cells (Fig. 2D and Fig. S1E ).
We next examined the pluripotency of iPSCs by examining the expression of germ layer-specific markers in embryoid body formation, which have been shown to promote spontaneous differentiation of ESCs and iPSCs. Our analysis of embryoid bodies demonstrated that each of our iPSCs were capable of differentiating into all three germ layers in vitro ( Fig. 3 and Fig. S3 ). Moreover, we also confirmed the in vivo differentiation capabilities of our iPSCs by showing teratoma formation upon intradermal injection of iPSCs into nude mice ( Fig. 3 and Fig. S3 ). We did not detect any differences in the characteristics of normal and PSiPSCs. Collectively, our findings indicate that the iPSCs we generated closely resemble human ESCs and other reported iPSCs (1, (3) (4) (5) (6) in all respects, suggesting successful generation of iPSCs not only from normal individuals, but also from two patients with RDEB.
Differentiation of Normal and RDEB Patient-Specific iPSCs into
Keratinocytes. We next defined a differentiation protocol to generate keratinocytes from our iPSCs in vitro. Although differentiation of iPSCs into keratinocytes has not yet been described, ESCs have previously been differentiated into epithelial lineages, including keratinocytes, by several methods (13) (14) (15) . Based on previous studies, we used retinoic acid (RA) to promote ectodermal fate (16) and bone morphogenetic protein 4 (BMP4) to block neural fate (17) , which can induce epithelial differentiation from ESCs. We also compared three different media previously reported to induce ectodermal differentiation, including differentiation medium (DM) (14) , FAD medium (see Methods for description) (13, 15) , and defined keratinocyte serum-free medium (KSFM), as initiation medium (Fig. 4A ).
iPSCs were cultured according to our modified protocol and we next studied marker progression along the keratinocyte lineage to determine their identity. We identified a large number of epithelial cells (Fig. 4B) , suggesting successful differentiation of iPSCs. Some of the induced epithelial cells were positive for keratin 14 (K14), a marker for keratinocytes, suggesting that RA and BMP4 have the potential to differentiate iPSCs into epithelial lineages, including keratinocytes. The differentiation efficiency to K14+ cells was highest (44.7 ± 9.7%) when defined KSFM was used as initiation medium compared with the other media ( Fig. 4C) . Furthermore, the percentage of K14+ cells in the differentiated population increased to over 70% (71.4 ± 10.5%) after the first passage, indicating that K14+ population can be enriched by culture condition (Fig. 4D) . We selected KSFM to use throughout the remainder of our studies. Under these conditions, we confirmed that all iPSC lines (both normal and patient specific) were differentiated into K14+ cells. Furthermore, in additionally differentiating ESCs into K14+ cells, we established that there was no significant difference in the differentiation efficiency between ESCs and iPSCs/PS-iPSCs (Fig. S4 ).
In addition, we used integrin α6 (ITGA6) and β4 (ITGB4) to enrich the K14+ population and remove the K14− population on day 30. By collecting the ITGA6 high /ITGB4 high population, the frequency of K14+ cells was markedly increased, for example, from 35.7% (on day 30) to 97.8% (on day 30), and the FACSsorted K14+ population also expressed desmoglein 3 (DSG3), an additional marker of basal keratinocytes (Fig. S5 ).
Characteristics and Differentiation Capacity of iPSC-Derived Keratinocytes.
We further examined the characteristics of the iPSC-derived cells to further define these keratinocyte-like properties. The stem cell markers SOX2, OCT4, ESG1, NANOG, and TERT were expressed in the iPSCs, but not in iPSC-derived K14+ cells after differentiation (Fig. S6) . We also confirmed that these cells expressed not only K14, but also other keratinocyte markers, including p63 (mainly ΔNp63), DSG3, ITGB4, laminin 5, and keratin 5 ( Fig. 5 and Fig. S6 ). Additionally, keratin 18, a marker of other epithelial cells that are not expressed in the skin, was similarly absent in these cells (Fig. S6) . As expected, type VII collagen was expressed in normal iPSC-derived K14+ cells, but not in the RDEB patient-specific iPSC-derived K14+ cells (Fig. 5) . Moreover, after culturing the induced cells in high calcium media to induce in vitro epidermal differentiation, they expressed keratin 1 (K1), a marker of epidermal differentiation (Fig. 5) , indicating that these iPSC-derived cells closely resemble normal human keratinocytes.
iPSC-derived keratinocytes could be expanded up to at least five passages in serum-free conditions without feeder layers. We checked viral transgene reactivation in iPSC-derived keratinocytes by qPCR and found that transgene reactivation was only rarely detected after differentiation into keratinocytes (2 of 24 transgenes in 6 iPSC-derived keratinocyte lines). Moreover, the transgene expression in iPS-derived keratinocytes, including cMYC and KLF4, was still silent or suppressed relative to those in the original iPSCs (Fig. S7) . Furthermore, no differences were detected in the process of generating keratinocytes from both normal and PSiPSCs. Except for the lack of expression of type VII collagen due to mutations, the characteristics of both the normal and the PS-iPSCderived keratinocytes were virtually identical.
Generation of 3D Skin Equivalents Using iPSC-Derived Keratinocytes.
We next generated 3D skin equivalents using normal and PS-iPSCderived keratinocytes (Fig. 6) . The 3D skin equivalents exhibited a multilayered epidermis and cornified layer at the surface of the epidermis, similar to those using normal human keratinocytes. Parakeratosis and separation along the basement membrane were nonspecific findings observed in all 3D skin equivalents, irrespective of the source of epidermal cells. We found that laminin 5 was expressed at the dermal-epidermal junction of these equivalents, and PS-iPSC-derived keratinocytes failed to express type VII collagen in 3D skin equivalents. Moreover, K1 was present only in the suprabasal layer, and loricrin, one of the terminal differentiation markers of the epidermis, was also observed in the upper layers of epidermis (Fig. 6) , suggesting that iPSCderived keratinocytes can be successfully matured and differentiated in 3D skin equivalents. These data suggested that iPSCs can be differentiated into fully functional keratinocytes in vitro, and 3D skin equivalents can be generated using keratinocytes derived from iPSCs.
Discussion
The reprogramming of a patient's somatic cells into iPSCs is a promising new approach to establish human models for studying disease mechanisms, testing drugs, and developing cell therapies. In fact, PS-iPSCs have already been generated from patients with several human diseases. It has recently been shown that PS-iPSCs from a patient with spinal muscular atrophy (SMA) can be generated and differentiated into motor neurons (4). SMA is caused by mutations in the SMN1 gene, resulting in the selective degeneration of lower α-motor neurons. Interestingly, these PSiPSC-derived motor neurons showed selective deficits compared with those derived from the patient's unaffected mother, indicating that PS-iPSCs can be used to model the specific pathology seen in genetically inherited disorders. More recently, Lee et al. (6) demonstrated the derivation of PS-iPSCs from a patient with familial dysautonomia (FD), a disease characterized by fatal peripheral neuropathy caused by mutations in the IKBKAP gene. The researchers also showed defects in IKBKAP splicing, neurogenesis, and migration in FD-iPSC-derived neural crest precursors, and used PS-iPSCs to evaluate the potency of candidate drugs in reversing aberrant splicing and ameliorating neural differentiation and migration. This study (6) was the first to show the utility of iPSCs for drug discovery. Together, these early studies revealed the promise of iPSC technology in providing new insights into the pathogenesis and treatment of human diseases. In the case of RDEB, although the pathomechanism of the disease is relatively well understood, effective treatment is still unavailable (8) . RDEB has been the subject of intense research over the past 20 y, and because it is a monogenic disorder, a cure would rely upon on the normal production of type VII collagen. Therefore, several current research approaches aim to restore collagen VII, including cell therapy (11, 12, (18) (19) (20) , gene therapy (11, 12, (18) (19) (20) , and, more recently, bone marrow transplantation (21, 22) . However, long-term success in treating RDEB is limited by the low proliferative capacity of keratinocytes and by the low efficiency of targeting the keratinocyte stem cell pool. Thus, the goals in developing a treatment for this disease would be to establish a robust source of pluripotent cells for the derivation of keratinocytes, and targeting keratinocyte stem cells for gene correction. This might be a difficult task to accomplish in vivo because the pool of stem cells in the skin is very limited. However, iPSCs have the potential to provide an unlimited source of patient-specific autologous cells that can eventually be used for skin grafting or transplantation without the need for conditioning or immunosuppression. While two recent papers reported the spontaneous differentiation of iPSCs into keratinocytes (23) , as well as the directed differentiation of mouse iPSCs into keratinocytes (24), evidence for directed differentiation of human iPSCs into keratinocytes has not yet been reported. Therefore, in this study, we generated iPSCs from normal individuals and two patients with RDEB to induce their differentiation into keratinocytes.
To generate iPSCs from both normal and affected fibroblasts, we used an established method first described by Takahashi et al. (1) . The efficiency of generating iPSCs from normal and affected individuals was similar, and the characteristics of both were comparable. We then modified existing experimental designs (13) (14) (15) and differentiated the iPSCs into keratinocytes, and subsequently, into functional 3D skin with markers of terminal epidermal differentiation. Our design differed from the previous reports in that the growth of iPSCs did not require feeder cells or animal sera. In our hands, fully functional keratinocytes were produced from the iPSCs in a shorter period and with greater efficiency than previous protocols (13) (14) (15) . The keratinocytes formed from both normal and PS-iPSCs were characteristically similar to normal keratinocytes, except that, as expected, they had COL7A1 mutations of the RDEB patients. The keratinocytes were able to differentiate into all epidermal layers in 3D skin equivalents in vitro. Moreover, 3D skin equivalents using PS-iPSC-derived keratinocytes demonstrated that it is possible to make in vitro disease models of skin diseases caused by loss of key proteins at BMZ. In addition, we demonstrated the potential methodology for enriching iPSC-derived keratinocytes from the differentiated cell pool. Taken together, our protocol has many advantages to derive proper keratinocytes from iPSCs for future clinical use, particularly because keratinocytes produce the majority of collagen VII in the skin in vivo (25) . Moreover, the iPSCs we produced had a very high proliferative capacity that can be used as a continuous source of keratinocytes in future therapies. Another major advantage of our methodology is the stability of transgene silencing after keratinocyte differentiation, especially c-MYC silencing, which when reactivated can lead to tumor formation (26) . However, such iPSC-based therapy requires proper quality and safety precautions, with one important concern regarding the therapeutic utility of iPSCs being viral transgene integration in iPSCs. In the future, due to rapid advancements in this field, it should be possible to generate gene integration-free iPSCs using several alternative methods, including plasmid (27) , recombinant protein (28), transposon (29) , integration-free virus vector (30) , and mRNA (31), although the efficiency for generating iPSCs with these methods is still improving.
To date, PS-iPSCs may not be directly used for regenerative medicine because of the underlying genetic defect in COL7A1 gene. In the future, we hope to genetically correct the genetic defect in the iPSCs obtained from patients with RDEB. Recently, the generation of genetically corrected iPSCs from the patients with Fanconi anemia (FA) was reported, along with the introduction of cDNA of a FA-related gene (FANCA or FANCD2) into patients' fibroblasts by lentivirus vector and generation of PSiPSCs from these manipulated fibroblasts (5). However, the lentiviral transgene was partially silenced in FA-PS-iPSCs. Although the genetic manipulation of iPSCs is still an emerging field, the application of new technologies is expected to enable sustained gene expression. We believe that one of the best strategies for correcting gene mutations is based on gene-targeting technology in PS-iPSCs. iPSCs are more suitable than keratinocytes for homologous recombination-based gene targeting because of their unlimited proliferation capability. An intriguing alternative for skin diseases is the readily available source of spontaneously corrected skin cells in the form of revertant mosaicism (32) . Occasionally, patients with different forms of EB and other skin diseases display patches of phenotypically normal skin where second-site mutations have resulted in a restoration of protein expression (32, 33). If we can establish iPSCs from such revertant patches of skin, then the gene correction step can be eliminated altogether, and a source of spontaneously corrected iPSCs can be generated and differentiated into skin. Building on the use of bone marrow transplantation in skin diseases such as RDEB (21, 22) , patientspecific iPSCs could be administered topically as well as systemically to ameliorate skin disease using an outside-in as well as an inside-out approach aimed at corrective therapy for RDEB.
Methods
Patient Information. The first patient with RDEB is a 13-mo-old boy, carrying compound heterozygous premature stop codon mutations in exon 5 (c609delC) and exon 75 (c6269delC) of the COL7A1 gene (Fig. S2) . The second patient is a 1.5-y-old boy with RDEB, carrying homozygous mutation designated c2305-14del10ins2 interrupting the splice junction of exon 17 with the 5′ splicing site of intron 17 (Fig. S2) . Both patients exhibited classic severe RDEB phenotypes with oral involvement and digit deformities on the hands and feet. Both skin biopsies were performed from the skin of upper thigh.
Generation of iPSCs. iPSCs were generated from human fibroblasts as previously described, with minor modifications (1). Human fibroblasts were isolated from normal foreskin and the skin of two patients with RDEB, and expanded in fibroblast medium (DMEM supplemented with 10% FBS; Invitrogen). These cells were transduced by pMXs-based retroviruses with four transcription factors: c-MYC, SOX2, OCT4, and KLF4. After 6 d, the transduced cells were reseeded on mitomycin C (MMC)-treated mouse embryonic fibroblast (MEF) in human ES cell medium (ESM: KO DMEM supplemented with 20% KO serum replacement, 1% GlutaMAX-I, 1% nonessential amino acid, 1% penicillin-streptomycin (Invitrogen), and 4 ng/mL basic FGF (R&D Systems) until colonies appeared. Colonies of iPS cells were mechanically picked up and replaced on MMC-treated MEF for expansion and characterization.
Mutation and DNA Fingerprinting Analysis of Patient-Specific iPSCs. Using the genomic DNA extracted from patient-specific iPSCs, exon 5 and 75 of COL7A1 with adjacent sequences of exon/intron borders were amplified by PCR using gene-specific primers (Table S1 ). The amplification conditions were 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 50 s, with a final extension at 72°C for 10 min. The amplified PCR products were directly sequenced in an ABI Prism 310 Automated Sequencer, using the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems). To confirm the origin of our PS-iPSCs, six microsatellite markers on different chromosomes were amplified by PCR using microsatellite-specific Fig. 6 . 3D skin equivalents using iPSC-derived keratinocytes. 3D skin equivalents were generated using not only hiPSC but also hiPS-RDEB. The multilayered epidermis expressed keratin 1, laminin 5, and loricrin in 3D skin equivalents using normal keratinocytes and hiPS, demonstrating that iPSCderived keratinocytes can be terminally differentiated in these skin equivalents. As expected, RDEB patient-specific keratinocytes failed to express type VII collagen. Clefting and parakeratosis are nonspecific findings observed in 3D skin equivalents. The gray line represents the dermal-epidermal boundary. E, epidermis; D, dermis. Characteristics and differentiation capacity of iPSC-derived keratinocytes. Both keratinocytes derived from normal (E-H) and PS-iPSCs (I-L) expressed keratinocyte markers, including keratin 14 (KRT14), p63 (A, E, and I) and desmoglein 3 (DSG3; B, F, and J), similar to normal human keratinocytes (nhKC; A-C). Type VII collagen (COL7A1) was only expressed by normal iPSC-derived keratinocytes (G), and not by PS-iPSC-derived keratinocytes (K) as expected from RDEB patients. Under high-calcium conditions, iPSCderived keratinocytes expressed keratin 1, indicative of epidermal differentiation (H and L).
primers (Table S1 ). The amplified PCR products were observed on 8% PAGE, and genotypes compared between the starting fibroblasts and PS-iPSCs.
Cell Culture and Directed Differentiation. iPSCs were maintained on MMCtreated MEF feeder layers in ESM. To confirm in vitro differentiation capacity of iPSCs into all three germ layers, embryoid bodies were made in differentiation medium (DM: ESM without bFGF) as previously described (1) . For enhancing spontaneous differentiation, embryoid bodies were attached on gelatin-coated chamber slides and incubated in fibroblast medium for 14 d before immunostaining. For keratinocyte differentiation, small clumps of iPSCs were subcultured on Matrigel (BD Biosciences) in MEF-conditioned ESM for 1 d. iPSCs were incubated in three different initiation mediums supplemented with 1 μM all-trans RA (Sigma) and 10 ng/mL BMP4 (R&D Systems) for 4 d. Three different initiation media were tested, including DM, FAD medium, and defined keratinocyte serum-free medium (KSFM; Invitrogen). FAD medium was combination of 90% DMEM/F12 (3:1), 10% FBS supplemented with 5 μg/mL insulin (EMD Chemicals), 0.4 μg/mL hydrocortisone (Sigma-Aldrich), 1.8 × 10 −4 M adenine (Sigma-Aldrich), 10 −10 M cholera toxin (ICN Pharmaceuticals), 3 × 10 −3 M Hepes buffer, 1% penicillin-streptomycin (Invitrogen), and 10 ng/mL recombinant human EGF (R&D Systems). After 4 d, initiation media were changed to KSFM, and iPSCs were maintained in culture until day 30. iPSC-derived keratinocytes were maintained in KSFM on the coated dishes with a coating medium containing 0.01 mg/mL of fibronectin (Sigma-Aldrich) and 0.03 mg/mL of collagen mixture (PureCol; Advanced BioMatrix). For differentiating iPSC-derived keratinocytes, cells were incubated in KSFM with a high calcium concentration (1.5 mM) for 4 d.
RT-PCR, PCR, and Quantitative PCR. RNA was extracted using an RNeasy Mini Kit (Qiagen), and DNA was removed by DNase treatment (Invitrogen) to avoid genomic DNA amplification. cDNA was synthesized using 2 μg RNA by SuperScript III reverse transcriptase and Oligo-dT primer (Invitrogen) according to the manufacturer's instructions. PCR reactions were performed with Platinum PCR SuperMix (Invitrogen). Quantitative PCR was performed on an ABI 7300 machine and analyzed with ABI Relative Quantification Study software (Applied Biosystems). Primers were designed according to ABI guidelines, and all reactions were performed using Power SYBR Green PCR Master Mix (Applied Biosystems). The following protocol was used: step 1, 50°C for 2 min; step 2, 95°C for 10 min; step 3, 95°C for 15 s; step 4, 60°C for 1 min; repeat steps 3 and 4 for 40 cycles. All samples were run in triplicate for three independent runs and normalized against an endogenous internal control, β2 microglobulin. All primer sequences are supplied in Table S1 .
FACS Analysis. The differentiated cells from iPSCs were enzymatically collected and fixed with 4% PFA/PBS for 5 min at room temperature. After PBS wash, cells were blocked and permeabilized in PBS with 10% goat serum and 0.1% saponin (Sigma-Aldrich). Primary antibodies (Table S2) were incubated for 1 h in PBS with 1% goat serum and 0.1% saponin. Normal IgG and no primary antibody were used as negative controls. After secondary antibody conjugated with fluorescence protein (Table S2) was reacted, cells were analyzed on BD LSRII Cell Analyzer by use of BD FACSDiva software (BD Biosciences) to calculate the differentiation efficiency of iPSCs into keratinocytes and analyze the differentiated population for enriching iPSC-derived keratinocytes.
Generation of 3D Skin Equivalents. 3D skin equivalents were generated on polycarbonate culture inserts (Nunc). Type I collagen matrix containing normal human fibroblasts isolated from foreskin was added on the insert and incubated at 37°C for 1 h to polymerize. After the polymerized matrix was incubated with fibroblast medium for 4-7 d, normal human keratinocytes and/ or iPSC-derived keratinocytes were reseeded on the matrix with SE medium I (see below) and incubated for 2 d. Medium was changed to SE medium II (see below) for 2 d. On day 5 after addition of keratinocytes, the culture composite was raised to the air interface and fed by feeding from below only with SE medium II to induce epidermal cornification, and 3D skin equivalents were 
